| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 1.6MM | - |
| Operating Income | -88.3MM | +93% |
| Operating Expenses | 89.9MM | +96% |
| Net Income | -93.6MM | +81% |
| R&D | 82.1MM | - |
| G&A | 7.8MM | -1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023.
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.
Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Find insights on Dentalcorp, Unnatural Products, Sanofi’s deal with Inhibrx, PolyNovo, and more in the latest Market Talks covering the Health Care sector.
Fourth-quarter earnings at United Airlines top Wall Street forecasts, while 3M posts better-than-expected adjusted earnings and sales but the stock tumbles on weak guidance.
Sanofi is getting into the liver disease treatment space with its $1.7 billion acquisition of biotech stock Inhibrx. But Sanofi stock toppled.
Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
The acquisition will give Sanofi an experimental drug for alpha-1 antitrypsin deficiency, while the rest of Inhibrx's assets will be spun into a new company.